logo UCSF Benioff Children's Hospital Oakland
Hematology/Oncology Department
Research Studies Open for Enrollment
Date: 07/13/2020

Neuro-Oncology:

Title ID/Protocol NCT/Phase Sponsor P.I. Contact
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) - PHASE 2 SUBPROTOCOL OF AG-120 (IVOSIDENIB) IN PATIENTS WITH TUMORS HARBORING IDH1 MUTATIONSAPEC1621K NCT04195555
Phase 2
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 MutationsACNS1721 03581292
Phase 2
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with CancerALTE1631 03223753
Phase 3
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Establishing Continuous Cell Lines and xenografts from Pediatric Cancers for Biological and Pre-Clinical Therapeutic StudiesABTR04B1 N/A
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome StudyAPEC14B1 N/A
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Genomic Analysis in Pediatric MalignanciesGenomics N/A
N/ATabitha Cooney, MDTabitha Cooney, MD
Phase 2 Study of everolimus for recurrent or progression low-grade gliomas in childrenPNOC001 NCT01734512
Phase 2
Pacific Pediatric Neuro-Oncology Consortium (PNOC)Caroline Hastings, MDCaroline Hastings, MD
Prospective multi-institutional study to assess the risk of radiation induced vasculopathy and stroke as well as stroke recurrence in children with cancer who received radiation therapy to the neck and/or brainRadART-Pro N/A
LaRoche FamilyJoseph Torkildson, MDJoseph Torkildson, MD
Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma PatientsACNS1422 02724579
Phase 2
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Clinical/Molecular Risk-Tailored Intensive, Compressed Induction Chemotherapy Followed by Consolidation Randomization To Single-Cycle or 3 Tandem Cycles of Marrow-Ablative Chemo with Hematopoietic Progenitor Cell RescueHead-Start-4 NCT02875314
Phase 4
Next Consortium, Nationwide Children'sCaroline Hastings, MDEffie Bourgin

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 • Phone: (510) 428-3000